Mylan Inc. has issued a clarification regarding its previous disclosure concerning the sale of equity shares in Biocon Limited. The company has rectified an inadvertent typographical error, correcting the post-disposal shareholding figure from 5.64% to Nil. This clarification ensures accurate reporting of Mylan Inc.’s stake in Biocon Limited, aligning with takeover regulations.
Mylan Inc. Clarifies Biocon Shareholding Disclosure
Mylan Inc. has submitted a crucial clarification to the stock exchanges concerning its previous disclosure dated 15 July 2026, which pertained to the sale of equity shares in Biocon Limited. The original disclosure had incorrectly stated Mylan Inc.’s post-disposal shareholding in Biocon Limited as 9,19,67,019 equity shares (5.64%).
Correction of Typographical Error
The company has now stated that this figure was an inadvertent typographical error. The correct shareholding of Mylan Inc. in Biocon Limited post the disposal of equity shares should have been reported as Nil. This revised disclosure is made to accurately reflect the seller’s holding following the transaction that occurred on 14 July 2026.
Regulatory Compliance
Mylan Inc. emphasizes that all other information presented in the original disclosure remains unchanged. The purpose of this supplementary disclosure is solely to rectify the aforementioned error. The company requests that this clarification be considered for the purposes of compliance with the relevant takeover regulations, given its rectificatory nature. The transaction itself was conducted via an open market sale.
Source: BSE
